ABSTRACT
Experiments were performed in order to evaluate the effects of fluoxetine, a selective inhibitor of neural serotonin transporter antidepressant, on the development lung metastases in rats subjected to laparotomy and injected (i.v.) with 10(4) Walker 256 (W-256) carcinosarcoma cells. The number of metastatic nodules on the surface of the lungs, as well as the percentage-area of metastases in the frontal section through pulmonary hilus were increased in rats subjected to sham-surgery or laparotomy. Treatment with fluoxetine (5 mg/kg) partially reversed those adverse effects of surgery, but the difference was clearer when it was administered before surgery was performed. Survival periods were also assessed and fluoxetine was found to decrease the lethality of rats exposed to surgery.
Subject(s)
Antidepressive Agents, Second-Generation/pharmacology , Antineoplastic Agents/pharmacology , Carcinoma 256, Walker/drug therapy , Carcinoma 256, Walker/secondary , Fluoxetine/pharmacology , Lung Neoplasms/drug therapy , Lung Neoplasms/secondary , Selective Serotonin Reuptake Inhibitors/pharmacology , Stress, Physiological/complications , Surgical Procedures, Operative/adverse effects , Animals , Male , Neoplasm Transplantation , Rats , Rats, Sprague-Dawley , Stress, Physiological/etiologyABSTRACT
The effect of the 21-aminosteroid tirilazad mesylate (10 mg/kg, i.p.) on nitric oxide synthase (NOS) activity in the brain cortex was studied in male Wistar rats subjected to cerebral global transient ischemia induced by bilateral clamping of the carotids for 10 min and reduction of arterial pressure (to 50 mm Hg) by intravenous infusion of 1.5 ml of a solution of trimethaphan (5 mg/ml). NOS activity was determined by measuring the rate of conversion of [3H]arginine to [3H]citrulline in brain cortex. Our results show for the first time that tirilazad suppresses the increase of NOS activity in brain cortex induced by cerebral ischemia (136 +/- 16 vs. 60 +/- 9 pmol [3H]citrulline/min per mg protein) and also suppresses the increase in K(m) of NOS (5.7 +/- 0.1 vs. 1.2 +/- 0.2 mumol/l). These effects are attributed to the fact that tirilazad acts as a scavenger of oxygen free radicals formed during cerebral ischemia. These results document the neuroprotective efficacy of tirilazad mesylate in cerebral ischemia.
Subject(s)
Brain/enzymology , Enzyme Inhibitors/pharmacology , Ischemic Attack, Transient/enzymology , Neuroprotective Agents/pharmacology , Nitric Oxide Synthase/antagonists & inhibitors , Pregnatrienes/pharmacology , Animals , Arginine/metabolism , Brain/drug effects , Citrulline/metabolism , Kinetics , Male , Rats , Rats, WistarABSTRACT
Experiments were conducted to evaluate the effects of desmethyl tirilazad (10 mg/kg, i.p.), a 21-aminosteroid, on constitutive nitric oxide synthase (cNOS) activity and cyclic guanosine monophosphate (cGMP) levels in brain homogenates of rats subjected to cerebral global transient ischemia induced by bilateral clamping of the carotids for 30 minutes and reduction of arterial pressure (to 50-60 mmHg) by intravenous infusion of 1.5 ml of a solution of trimethaphan (5 mg/ml). Our results show that ischemia induces a rise in cNOS activity (from 62.0 +/- 6.1 to 133.3 +/- 13.3 pmol/min/mg protein) and cGMP levels (from 459.3 +/- 49.6 to 1074.1 +/- 132.1 fmol/mg protein). Pretreatment with desmethyl tirilazad abolishes these increases. These results are in agreement with the neuroprotective efficacy of desmethyl tirilazad in cerebral ischemia.
